Berberine was supposedly used in China as a broad-spectrum anti-microbial medicine by Shennong around 3000 BC. This first recorded use of Berberine is described in the ancient Chinese medical book The Divine Farmer's Herb-Root Classic.
As a Chinese traditional medicine or dietary supplement, berberine has shown some activity against fungal infections, Candida albicans, yeast, parasites, and bacterial/viral infections. Berberine seems to exert synergistic effects with fluconazole even in drug-resistant C. albicans infections.
Some research has been undertaken into possible use against MRSA infection.
Berberine is a component of some eye drop formulations. There is some evidence it is useful in the treatment of trachoma, and it has been a standard treatment for leishmaniasis.
Berberine prevents and suppresses proinflammatory cytokines, E-selectin, and genes, and increases adiponectin expression which partly explains its versatile health effects. Berberine is a nucleic acid-binding isoquinoline alkaloid with wide potential therapeutic properties.
Newer and experimental uses
Diabetes, dyslipidemias and cardiovascular conditions
During the last few decades, many studies have shown berberine has various beneficial effects on the cardiovascular system and significant anti-inflammatory activities. A Canadian report suggested berberine can effectively reduce intracellular superoxide levels in LPS-stimulated macrophages. Such a restoration of cellular redox by berberine is mediated by its selective inhibition of gp91phox expression and enhancement of SOD activity.
Berberine exerts up-regulating activity on both the low-density-lipoprotein receptor (LDLR) and the insulin receptor (InsR). This one-drug-multiple-target characteristic might be suitable for the treatment of metabolic syndrome.
Berberine has been shown to lower elevated blood glucose as effectively as metformin. The mechanisms of action include inhibition of aldose reductase, inducing glycolysis, preventing insulin resistance through increasing insulin receptor expression and acting like incretins. A new study suggested berberine may overcome insulin resistance via modulating key molecules in insulin signaling pathway, leading to increased glucose uptake in insulin-resistant cells.
Berberine might exert its insulinotropic effect in isolated rat islets by up-regulating the expression of hepatocyte nuclear factor 4 alpha, which probably acts solely or together with other HNFs to modulate glucokinase activity, rendering β cells more sensitive to glucose fluctuation and to respond more effectively to glucose challenge.
Berberine seems to inhibit human dipeptidyl peptidase-4 (DPP4), as well as the prodiabetic target human protein tyrosine phosphatase 1B (h-PTP 1B), which explain at least some of its antihyperglycemic activities. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states.
A recent comprehensive metabonomics method, applied to 60 type 2 diabetics, suggested administration of berberine down-regulates the high level of free fatty acids which are known to be toxic to the pancreas and cause insulin resistance. These results suggest berberine might play a pivotal role in the treatment of type 2 diabetes, concluded the authors.
Berberine has been shown to boost the effects of metformin and 2,4-thiazolidinedione (TZD), and can partly replace the commercial drugs, which could lead to a reduction in toxicity and side effects of the latter.
Berberine inhibits FOXO1, which integrates insulin signaling with mitochondrial function. Inhibition of Foxo1 can improve hepatic metabolism during insulin resistance and the metabolic syndrome.
Berberine lowers elevated blood total cholesterol, LDL cholesterol, triglycerides and atherogenic apolipoproteins (apo B) (Apo B), but the mechanism of action is distinct from that of statins. Berberine reduces LDL cholesterol by upregulating LDLR mRNA expression posttranscriptionally while downregulating the transcription of proprotein convertase subtilisin/kexin type 9 (PCSK9), a natural inhibitor of LDL receptor (LDLR), and increasing in the liver the expression of LDL receptors through extracellular signal-regulated kinase (ERK) signaling pathway, while statins inhibit cholesterol synthesis in the liver by blocking HMG-CoA-reductase. This explains why berberine does not cause side effects typical of statins. Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters.
Berberine reduces hepatic fat content in rats with nonalcoholic fatty liver disease. Berberine also prevents proliferation of hepatic stellate cells (HSCs), which are central for the development of fibrosis during liver injury.
According to a Chinese report, combined use of berberine with cyclosporin A (CsA) could markedly increase the blood concentration of CsA and reduce the dosage of CsA required, save the cost for medical service, and shows no obvious adverse reaction in heart-transplant recipients.
Berberine has drawn extensive attention towards its antineoplastic effects. It seems to suppress the growth of a wide variety of tumor cells, including breast cancer, leukemia, melanoma, epidermoid carcinoma, hepatoma, pancreatic cancer, oral carcinoma, tongue carcinoma, glioblastoma, prostate carcinoma and gastric carcinoma. Animal studies have shown that berberine can suppress chemical-induced carcinogenesis, clastogenesis, tumor promotion, tumor invasion,prostate cancer, neuroblastoma, and leukemia.
It is a radiosensitizer of tumor cells, but not of normal cells. How berberine mediates these effects is not fully understood, but its ability to inhibit angiogenesis and to modulate Mcl-1, Bcl-xL, cyclooxygenase (COX)-2, MDR, tumor necrosis factor (TNF)- and IL-6, iNOS, IL-12, intercellular adhesion molecule-1 and ELAM-1 expression, MCP-1 and CINC-1, cyclin D1, activator protein (AP-1), HIF-1, PPAR-, and topoisomerase II has been shown. By using yeast mutants, berberine was found to bind and inhibit stress-induced mitogen-activated protein kinase kinase activation. Because apoptotic, carcinogenic, and inflammatory effects and various gene products (such as TNF-α, IL-6, COX-2, adhesion molecules, cyclin D1, and MDR) modulated by berberine are regulated by the transcription factor nuclear factor- B (NF- B), it is postulated this pathway plays a major role in the action of berberine. Berberine suppressed NF-κB activation induced by various inflammatory agents and carcinogens. This alkaloid also suppressed constitutive NF-κB activation found in certain tumor cells. It seems to protect against side effects of radiation therapy in lung cancer. However, new studies suggest that while berberine decreases cell growth, it increases the side population (stem cell) fraction of H460 lung cancer cells. In lung cancer it can also act through suppression of TGF-β1-induced epithelial-to-mesenchymal transition. Berberine enhances chemosensitivity to some chemotherapeutic agents like irinotecan .
Berberine, 300 mg three times a day orally, also seems to inhibit complication of abdominal or pelvic radiation, called radiation-induced acute intestinal symptoms. The studies suggest its use in clinical development may be more as a cytostatic agent than a cytotoxic compound.
Berberine seems to act as an herbal antidepressant and a neuroprotector against neurodegenerative disorders. Berberine inhibits prolyl oligopeptidase (POP) in a dose-dependent manner. Berberine is also known to bind to sigma receptors like many synthetic antidepressant drugs. As berberine is a natural compound that has been safely administered to humans, preliminary results suggest the initiation of clinical trials in patients with depression, bipolar affective disorder, schizophrenia, or related diseases in which cognitive capabilities are affected, with either the extract or pure berberine. New experimental results suggest berberine may have a potential for inhibition and prevention of Alzheimer's disease (AD), mainly through both cholinesterase (ChEs) inhibitory and β-amyloids pathways, and additionally through antioxidant capacities.
Other studies have shown berberine to increase noradrenaline and serotonin levels in the brain (rats) while inhibiting dopaminergic activity. The half-life of berberine in vivo seems to be three to four hours, thus suggesting administration three times a day if steady levels are to be achieved.
Berberine can ameliorate proinflammatory cytokines-induced intestinal epithelial tight junction damage in vitro, and berberine may be one of the targeted therapeutic agents that can restore barrier function in intestinal disease states.
A new study identified a key cellular mechanism underlying the protective effect of berberine on HIV PI-induced inflammatory response in macrophages. Modulation of the endoplasmic reticulum stress response represents a potential therapeutic target for various inflammatory diseases and metabolic syndromes, including HIV PI-associated atherosclerosis. The report shows the potential application of berberine as a complementary therapeutic agent for HIV infection.
Berberine use in newborns has been associated with kernicterus, a bilirubin-induced brain dysfunction. Also, at dosages about 60-100 times as large as a human pharmacological dose, a small dose-response teratogenic effect was observed in rodents. For these reasons, berberine is not usually recommended for use during pregnancy, although there are some reason to believe that this may not be harmful.
Biosynthesis of berberine
The alkaloid berberine has a tetracyclic skeleton derived from a benzyltetrahydroisoquinoline system with the incorporation of an extra carbon atom provided by S-adenosyl methionine (SAM) via an N-methyl group. Formation of the berberine bridge is readily rationalized as an oxidative process in which the N-methyl group is oxidized to an iminium ion, and a cyclization to the aromatic ring occurs by virtue of the phenolic group.
Reticuline is known as the immediate precursor of protoberberine alkaloids in plants. Berberine is an alkaloid derived from tyrosine. L-DOPA and 4-hydroxypyruvic acid both come from L-Tyr. Although two tyrosine molecules are used in the biosynthetic pathway, only the phenylethylamine fragment of the tetrahydroisoquinoline ring system is formed via DOPA, the remaining carbon atoms come from tyrosine via 4-hydroxyphenylacetaldehyde. L-DOPA loses carbon dioxide to form dopamine1. Likewise, 4-hydroxypyruvic acid also loses carbon dioxide to form 4-hydroxyphenyl-acetaldehyde 2. Dopamine1 then reacts with 4-hydroxy-phenylacetaldehyde 2 to form (S)-norcolaurine 3 in a reaction similar to the Mannich reaction. After oxidation and methylation by SAM, (S)-reticuline4 is formed. (S)-reticuline serves as a pivotal intermediate to other alkaloids. Oxidation of the tertiary amine then occurs and an iminium ion is formed 5. In a Mannich-like reaction the ortho position to the phenol is nucleophilic, and electrons are pushed to form 6. Product 6 then undergoes keto-enol tautomerism to form (S)-scoulerine, which is then methylated by SAM to form (S)-tetrahydrocolumbamine 7. Product 7 is then oxidized to form the methylenedioxy ring from the ortho-methoxyphenol, via an O2-, NADPH- and cytochrome P-450-dependent enzyme, giving (S)-canadine 8. (S)-canadine is then oxidized to give the quaternary isoquinolinium system of berberine. This happens in two separate oxidation steps, both requiring molecular oxygen, with H2O2 and H2O produced in the successive processes.
Sanguinarine, a plant-based compound with very similar chemical classification as berberine
Coptisine for a related pharmacological discussion
Goldenseal for a related pharmacological discussion
^Zhang, Q; Cai, L; Zhong, G; Luo, W (2010). "Simultaneous determination of jatrorrhizine, palmatine, berberine, and obacunone in Phellodendri Amurensis Cortex by RP-HPLC". Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica35 (16): 2061–4. doi:10.4268/cjcmm20101603. PMID21046728.
^Xu Y, Wang Y, Yan L et al. (November 2009). "Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation". Journal of Proteome Research8 (11): 5296–304. doi:10.1021/pr9005074. PMID19754040.
^Yu HH, Kim KJ, Cha JD et al. (2005). "Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus". Journal of Medicinal Food8 (4): 454–61. doi:10.1089/jmf.2005.8.454. PMID16379555.
^Zhang, Shulin; Zhang, Bo; Xing, Kezhi; Zhang, Xiumei; Tian, Xiuping; Dai, Wei (2010). "Inhibitory effects of golden thread (Coptis chinensis) and berberine on Microcystis aeruginosa". Water Science & Technology61 (3): 763. doi:10.2166/wst.2010.857.
^Babbar OP, Chhatwal VK, Ray IB, Mehra MK (December 1982). "Effect of berberine chloride eye drops on clinically positive trachoma patients". The Indian Journal of Medical Research76 (Suppl): 83–8. PMID7185757.
^Wang, Yan-Xiang; Wang, Yu-Ping; Zhang, Hao; Kong, Wei-Jia; Li, Ying-Hong; Liu, Fei; Gao, Rong-Mei; Liu, Ting et al. (November 2009). "Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor". Bioorganic & Medicinal Chemistry Letters19 (21): 6004–8. doi:10.1016/j.bmcl.2009.09.059. PMID19800225.
^Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L (March 2010). "Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats". Metabolism: Clinical and Experimental60 (2): 298–305. doi:10.1016/j.metabol.2010.02.005. PMID20304443.
^Wang C, Li J, Lv X et al. (August 2009). "Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high fat diet and streptozotocin". European Journal of Pharmacology620 (1–3): 131–7. doi:10.1016/j.ejphar.2009.07.027. PMID19686728.
^ abZhang H, Wei J, Xue R et al. (September 2009). "Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression". Metabolism: Clinical and Experimental59 (2): 285–92. doi:10.1016/j.metabol.2009.07.029. PMID19800084.
^ abWang JM, Yang Z, Xu MG et al. (July 2009). "Berberine-induced decline in circulating CD31+/CD42- microparticles is associated with improvement of endothelial function in humans". European Journal of Pharmacology614 (1–3): 77–83. doi:10.1016/j.ejphar.2009.04.037. PMID19401197.
^Zhang Y, Li X, Zou D et al. (July 2008). "Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine". The Journal of Clinical Endocrinology and Metabolism93 (7): 2559–65. doi:10.1210/jc.2007-2404. PMID18397984.
^Liu L, Yu YL, Yang JS et al. (March 2010). "Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study". Naunyn-Schmiedeberg's Archives of Pharmacology381 (4): 371–81. doi:10.1007/s00210-010-0502-0. PMID20229011.
^Prabhakar, PK; Doble, M (August 2009). "Synergistic effect of phytochemicals in combination with hypoglycemic drugs on glucose uptake in myotubes". Phytomedicine16 (12): 1119–26. doi:10.1016/j.phymed.2009.05.021. PMID19660925.
^ abSun X, Zhang X, Hu H et al. (September 2009). "Berberine inhibits hepatic stellate cell proliferation and prevents experimental liver fibrosis". Biological & Pharmaceutical Bulletin32 (9): 1533–7. doi:10.1248/bpb.32.1533. PMID19721228.
^Cheng Z, Guo S, Copps K et al. (November 2009). "Foxo1 integrates insulin signaling with mitochondrial function in the liver". Nature Medicine15 (11): 1307–11. doi:10.1038/nm.2049. PMID19838201.
^Zhou JY, Zhou SW, Zhang KB et al. (June 2008). "Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats". Biological & Pharmaceutical Bulletin31 (6): 1169–76. doi:10.1248/bpb.31.1169. PMID18520050.
^Holy EW, Akhmedov A, Lüscher TF, Tanner FC (February 2009). "Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells". Journal of Molecular and Cellular Cardiology46 (2): 234–40. doi:10.1016/j.yjmcc.2008.10.011. PMID19014947.
^Kong W, Wei J, Abidi P et al. (December 2004). "Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins". Nature Medicine10 (12): 1344–51. doi:10.1038/nm1135. PMID15531889.
^Kim WS, Lee YS, Cha SH et al. (April 2009). "Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity". American Journal of Physiology– Endocrinology and Metabolism296 (4): E812–9. doi:10.1152/ajpendo.90710.2008. PMID19176354.
^Abidi P, Zhou Y, Jiang JD, Liu J (October 2005). "Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine". Arteriosclerosis, Thrombosis, and Vascular Biology25 (10): 2170–6. doi:10.1161/01.ATV.0000181761.16341.2b. PMID16100034.
^Wang, Yanwen; Jia, Xiaoming; Ghanam, Khadija; Beaurepaire, CéCile; Zidichouski, Jeffrey; Miller, Lisa (2009). "Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters". Atherosclerosis209 (1): 111–7. doi:10.1016/j.atherosclerosis.2009.08.050. PMID19782362.
^ abWang Y, Huang Y, Lam KS et al. (June 2009). "Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase". Cardiovascular Research82 (3): 484–92. doi:10.1093/cvr/cvp078. PMID19251722.
^Turner N, Li JY, Gosby A et al. (May 2008). "Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action". Diabetes57 (5): 1414–8. doi:10.2337/db07-1552. PMID18285556.
^Lee YS, Kim WS, Kim KH et al. (August 2006). "Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states". Diabetes55 (8): 2256–64. doi:10.2337/db06-0006. PMID16873688.
^Jeong HW, Hsu KC, Lee JW et al. (April 2009). "Berberine suppresses proinflammatory responses through AMPK activation in macrophages". American Journal of Physiology– Endocrinology and Metabolism296 (4): E955–64. doi:10.1152/ajpendo.90599.2008. PMID19208854.
^Huang Z, Wang L, Meng S, Wang Y, Chen T, Wang C (July 2009). "Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages". International Journal of Cardiology146 (2): 153–158. doi:10.1016/j.ijcard.2009.06.023. PMID19576641.
^Huang WM, Yan H, Jin JM, Yu C, Zhang H (December 1992). "Beneficial effects of berberine on hemodynamics during acute ischemic left ventricular failure in dogs". Chinese Medical Journal105 (12): 1014–9. PMID1299549.
^Marin-Neto JA, Maciel BC, Secches AL, Gallo Júnior L (April 1988). "Cardiovascular effects of berberine in patients with severe congestive heart failure". Clinical Cardiology11 (4): 253–60. doi:10.1002/clc.4960110411. PMID3365876.
^Zeng XH, Zeng XJ, Li YY (July 2003). "Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy". The American Journal of Cardiology92 (2): 173–6. doi:10.1016/S0002-9149(03)00533-2. PMID12860219.
^Wu M., Wang J., Liu L.-T. "Advance of studies on anti-atherosclerosis mechanism of berberine", Chinese Journal of Integrative Medicine 2010 16:2 (188-192)
^Huang XS, Yang GF, Pan YC (August 2008). "[Effect of berberin hydrochloride on blood concentration of cyclosporine A in cardiac transplanted recipients]". Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi (in Chinese) 28 (8): 702–4. PMID18928093.
^Sun Y, Xun K, Wang Y, Chen X (October 2009). "A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs". Anticancer Drugs20 (9): 757–69. doi:10.1097/CAD.0b013e328330d95b. PMID19704371.
^Tang J, Feng Y, Tsao S et al. (August 2009). "Berberine and Coptidis Rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations". Journal of Ethnopharmacology126 (1): 5–17. doi:10.1016/j.jep.2009.08.009. PMID19686830.
^Kim JB, Yu JH, Ko E et al. (October 2009). "The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest". Phytomedicine17 (6): 436–40. doi:10.1016/j.phymed.2009.08.012. PMID19800775.
^Serafim TL, Oliveira PJ, Sardao VA, Perkins E, Parke D, Holy J (May 2008). "Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line". Cancer Chemotherapy and Pharmacology61 (6): 1007–18. doi:10.1007/s00280-007-0558-9. PMID17661039.
^Pinto-Garcia L, Efferth T, Torres A, Hoheisel JD, Youns M (May 2010). "Berberine Inhibits Cell Growth and Mediates Caspase-Independent Cell Death in Human Pancreatic Cancer Cells". Planta Medica76 (11): 1155–61. doi:10.1055/s-0030-1249931. PMID20455200.
^Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB (July 2008). "Berberine modifies cysteine 179 of IκBα kinase, suppresses nuclear factor-κB-regulated antiapoptotic gene products, and potentiates apoptosis". Cancer Research68 (13): 5370–9. doi:10.1158/0008-5472.CAN-08-0511. PMID18593939.
^Kim JB, Ko E, Han W, Shin I, Park SY, Noh DY (November 2008). "Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells". Planta Medica74 (14): 1693–700. doi:10.1055/s-0028-1088313. PMID18951337.
^Kim S, Choi JH, Kim JB et al. (2008). "Berberine suppresses TNF-α-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells". Molecules13 (12): 2975–85. doi:10.3390/molecules13122975. PMID19052522.
^Thirupurasundari CJ, Padmini R, Devaraj SN (February 2009). "Effect of berberine on the antioxidant status, ultrastructural modifications and protein bound carbohydrates in azoxymethane-induced colon cancer in rats". Chemico-biological Interactions177 (3): 190–5. doi:10.1016/j.cbi.2008.09.027. PMID18951886.
^Mantena SK, Sharma SD, Katiyar SK (February 2006). "Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells". Molecular Cancer Therapeutics5 (2): 296–308. doi:10.1158/1535-7163.MCT-05-0448. PMID16505103.
^Wang GY, Lv QH, Dong Q, Xu RZ, Dong QH (2009). "Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice". Journal of Asian Natural Products Research11 (3): 219–28. doi:10.1080/10286020802675076. PMID19408145.
^Lin CC, Ng LT, Hsu FF, Shieh DE, Chiang LC (January 2004). "Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth". Clin. Exp. Pharmacol. Physiol.31 (1–2): 65–9. doi:10.1111/j.1440-1681.2004.03951.x. PMID14756686.
^Khan M, Giessrigl B, Vonach C et al. (January 2010). "Berberine and a Berberis lycium extract inactivate Cdc25A and induce α-tubulin acetylation that correlate with HL-60 cell cycle inhibition and apoptosis". Mutation Research683 (1–2): 123–30. doi:10.1016/j.mrfmmm.2009.11.001. PMID19909759.
^Liu Y, Yu H, Zhang C et al. (November 2008). "Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-β-1 in patients with lung cancer". European Journal of Cancer44 (16): 2425–32. doi:10.1016/j.ejca.2008.07.040. PMID18789680.
^Li GH, Wang DL, Hu YD et al. (September 2009). "Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy". Medical Oncology (Northwood, London, England)27 (3): 919–25. doi:10.1007/s12032-009-9307-8. PMID19757213.
^Kulkarni, Sk; Dhir, A (July 2009). "sigma-1 receptors in major depression and anxiety". Expert Review of Neurotherapeutics9 (7): 1021–34. doi:10.1586/ern.09.40. PMID19589051.
^Kulkarni SK, Dhir A (December 2009). "Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders". Phytotherapy Research24 (3): 317–24. doi:10.1002/ptr.2968. PMID19998323.
^Xiang J, Yu C, Yang F (December 2009). "Conformation-activity studies on the interaction of berberine with acetylcholinesterase: Physical chemistry approach". Progress in Natural Science19 (12): 1721–5. doi:10.1016/j.pnsc.2009.07.010.
^Huang L, Shi A, He F, Li X (December 2009). "Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors". Bioorganic & Medicinal Chemistry18 (3): 1244–51. doi:10.1016/j.bmc.2009.12.035. PMID20056426.
^Jung HA, Min BS, Yokozawa T, Lee JH, Kim YS, Choi JS (August 2009). "Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids". Biological & Pharmaceutical Bulletin32 (8): 1433–8. doi:10.1248/bpb.32.1433. PMID19652386.
^Peng WH, Lo KL, Lee YH, Hung TH, Lin YC (August 2007). "Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice". Life Sciences81 (11): 933–938. doi:10.1016/j.lfs.2007.08.003. PMID17804020.
^Zhao YN, Ding Y, Wang RF, Xing DM, Cheng J, Du L (2004). "A new approach to investigate the pharmacokinetics of traditional chinese medicine YL2000". The American journal of Chinese Medicine32 (6): 921–929. doi:10.1142/S0192415X04002521. PMID15673197.
^Li, Ning; Gu, Lili; Qu, Linlin; Gong, Jianfeng; Li, Qiurong; Zhu, Weiming; Li, Jieshou (2010). "Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells". European Journal of Pharmaceutical Sciences40 (1): 1–8. doi:10.1016/j.ejps.2010.02.001. PMID20149867.
^Gu, L; Li, N; Gong, J; Li, Q; Zhu, W; Li, J (2011). "Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia". The Journal of infectious diseases203 (11): 1602–12. doi:10.1093/infdis/jir147. PMID21592990.
^Jahnke, Gloria D.; Price, Catherine J.; Marr, Melissa C.; Myers, Christina B.; George, Julia D. journal=Birth defects research (Part B, Developmental and reproductive toxicology) (2006). "Developmental toxicity evaluation of berberine in rats and mice". Birth Defects Res B Dev Reprod Toxicol77 (3): 201–8. doi:10.1002/bdrb.20075. PMID16634078.